Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Equities researchers at Piper Jaffray Companies dropped their FY2019 earnings per share (EPS) estimates for Halozyme Therapeutics in a research report issued on Wednesday, November 13th. Piper Jaffray Companies analyst J. Catanzaro now expects that the biopharmaceutical company will post earnings of ($0.42) per share for the year, down from their previous forecast of ($0.23). Piper Jaffray Companies also issued estimates for Halozyme Therapeutics’ Q4 2019 earnings at ($0.17) EPS, Q1 2020 earnings at ($0.01) EPS, Q2 2020 earnings at $0.10 EPS, Q3 2020 earnings at $0.19 EPS, Q4 2020 earnings at $0.27 EPS, FY2020 earnings at $0.55 EPS, Q1 2021 earnings at $0.23 EPS, Q2 2021 earnings at $0.26 EPS, Q3 2021 earnings at $0.32 EPS, FY2021 earnings at $1.18 EPS, FY2022 earnings at $2.05 EPS and FY2023 earnings at $2.33 EPS.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.05). The business had revenue of $46.20 million for the quarter, compared to the consensus estimate of $54.96 million. Halozyme Therapeutics had a negative net margin of 19.73% and a negative return on equity of 15.59%. Halozyme Therapeutics’s revenue was up 80.5% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.19) earnings per share.

A number of other brokerages have also weighed in on HALO. JPMorgan Chase & Co. raised their price objective on Halozyme Therapeutics from $20.00 to $23.00 and gave the company an “overweight” rating in a research report on Wednesday. ValuEngine lowered Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, October 21st. BidaskClub lowered Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, September 27th. BMO Capital Markets lifted their price target on Halozyme Therapeutics from $16.00 to $17.00 and gave the stock a “market perform” rating in a research report on Wednesday. Finally, Zacks Investment Research upgraded Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating and set a $18.00 price target for the company in a research report on Thursday, November 7th. Four investment analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $20.33.

Shares of Halozyme Therapeutics stock opened at $18.49 on Friday. The firm has a market cap of $2.45 billion, a price-to-earnings ratio of -33.02 and a beta of 1.78. The business has a 50-day moving average price of $15.80 and a 200-day moving average price of $16.16. The company has a quick ratio of 2.57, a current ratio of 2.89 and a debt-to-equity ratio of 0.05. Halozyme Therapeutics has a twelve month low of $13.24 and a twelve month high of $18.74.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its stake in shares of Halozyme Therapeutics by 8.0% during the second quarter. BlackRock Inc. now owns 12,625,128 shares of the biopharmaceutical company’s stock valued at $216,900,000 after acquiring an additional 929,980 shares in the last quarter. Invesco Ltd. lifted its holdings in Halozyme Therapeutics by 28.2% during the 2nd quarter. Invesco Ltd. now owns 5,387,409 shares of the biopharmaceutical company’s stock worth $92,555,000 after buying an additional 1,183,551 shares in the last quarter. William Blair Investment Management LLC lifted its holdings in Halozyme Therapeutics by 774.0% during the 2nd quarter. William Blair Investment Management LLC now owns 3,538,927 shares of the biopharmaceutical company’s stock worth $60,799,000 after buying an additional 3,134,003 shares in the last quarter. FMR LLC lifted its holdings in Halozyme Therapeutics by 5.0% during the 1st quarter. FMR LLC now owns 2,685,575 shares of the biopharmaceutical company’s stock worth $43,238,000 after buying an additional 127,379 shares in the last quarter. Finally, Northern Trust Corp lifted its holdings in Halozyme Therapeutics by 0.5% during the 2nd quarter. Northern Trust Corp now owns 1,790,475 shares of the biopharmaceutical company’s stock worth $30,760,000 after buying an additional 8,377 shares in the last quarter. Institutional investors own 84.35% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.

Featured Story: Stop Order Uses For Individual Investors

Earnings History and Estimates for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.